Arcutis posted Q2 net product revenue of $129.9m, up 59% year-on-year, and lifted its full-year sales guidance to $525m–$540m.

The Colorado-based lung diagnostics company reported $26.9m in Q2 revenue and maintained full-year guidance of $108–114m.

Phase 2 data show silevertinib achieved a 60% ORR and 86% CNS response in frontline non-classical EGFRm NSCLC, with no de novo brain metastases

BriaCell's next-generation personalised cell-based immunotherapy for prostate cancer can now enter a Phase 1/2a trial after receiving FDA IND clearance.

The zinc-based storage company grew Q2 revenue to $68.8m but tightened its full-year outlook to $300m–$350m as manufacturing consolidation weighs on

Eton has acquired US rights to topical timolol gel ASN-001, targeting moderate infantile hemangiomas with an NDA filing planned for late 2027.

IQVIA will provide clinical and regulatory infrastructure to Medera's AAV gene therapy and human cardiac tissue modelling platforms.

NewAmsterdam Pharma secured a positive CHMP opinion for obicetrapib in Europe as its 9,500-patient PREVAIL outcomes trial heads toward an interim readout.

The Danish pharma giant raised its full-year adjusted sales and operating profit guidance, citing higher-than-expected demand for its GLP-1 product portfolio.

Sanofi's first-in-human trial of oral STAT6 degrader SAR448272 triggers a milestone payment, bringing Nurix's total collaboration receipts to roughly $139m.

SCI-110, a cannabinoid combination candidate, is now being tested across three global sites after Phase IIa data showed a 21% average tic reduction.

Altimmune has started enrolling patients in its global registrational PERFORMA study, with a 52-week data readout anticipated in 2029.